

Office of Regulatory Management  
Economic Review Form

<b>Agency name</b>	Virginia Department of Health
<b>Virginia Administrative Code (VAC) Chapter citation(s)</b>	12VAC5-90
<b>VAC Chapter title(s)</b>	Regulations for Disease Reporting and Control
<b>Action title</b>	12VAC5-90 Periodic Review
<b>Date this document prepared</b>	2/28/24
<b>Regulatory Stage (including Issuance of Guidance Documents)</b>	Periodic Review

**Cost Benefit Analysis**

Complete Tables 1a and 1b for all regulatory actions. You do not need to complete Table 1c if the regulatory action is required by state statute or federal statute or regulation and leaves no discretion in its implementation.

Table 1a should provide analysis for the regulatory approach you are taking. Table 1b should provide analysis for the approach of leaving the current regulations intact (i.e., no further change is implemented). Table 1c should provide analysis for at least one alternative approach. You should not limit yourself to one alternative, however, and can add additional charts as needed.

Report both direct and indirect costs and benefits that can be monetized in Boxes 1 and 2. Report direct and indirect costs and benefits that cannot be monetized in Box 4. See the ORM Regulatory Economic Analysis Manual for additional guidance.

**Impact on Local Partners**

Use this chart to describe impacts on local partners. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 2: Impact on Local Partners**

(1) Direct & Indirect Costs & Benefits (Monetized)	<p>This Periodic Review decision does not change the impact on local partners.</p> <p>Direct Costs: Any medical care facilities owned/operated by local government, such as local health departments, are affected by this</p>
--	--

	<p>regulation. Local health departments will continue to incur personnel costs related to the mandatory response to reportable disease outbreaks.</p> <p>Actual costs are difficult to quantify as costs will vary based on the salary of the employee performing each of these duties, the volume of reportable disease cases, and employee efficiency while performing assigned duties. For the purposes of this form, VDH has assumed that all monetizable costs will be borne by local health departments.</p> <p>Indirect Costs: \$0</p> <p>Direct Benefits: \$0</p> <p>Indirect Benefits: \$0</p>	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0 (but see explanation above)	(b) \$0 (but see explanation above)
(3) Other Costs & Benefits (Non-Monetized)	<p>Benefits:</p> <p>(1) Achieve more complete and efficient reporting of diseases of public health importance to VDH so that actions can be taken to minimize the spread of diseases across the Commonwealth.</p> <p>(2) Gain a better understanding of the scope and magnitude of reportable public health conditions in Virginia.</p>	
(4) Assistance	There is no additional assistance needed for local partners as a result of this periodic review decision.	
(5) Information Sources	None	

**Impacts on Families**

Use this chart to describe impacts on families. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 3: Impact on Families**

(1) Direct & Indirect Costs & Benefits (Monetized)	<p>This Periodic Review decision does not change the impact on families.</p> <p>Direct Costs: \$0</p> <p>Indirect Costs: \$0</p>
--	--

	Direct Benefits: \$0	
	Indirect Benefits: \$0	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0	(b) \$0
(3) Other Costs & Benefits (Non-Monetized)	Benefits: (1) Achieve more complete and timely reporting of diseases of public health importance to VDH. This allows VDH to take actions to minimize the spread of disease across the Commonwealth. (2) Persons diagnosed with or exposed to a reportable disease will be supported with education about their condition and ways to protect their health and the health of others.	
(4) Information Sources	None	

**Impacts on Small Businesses**

Use this chart to describe impacts on small businesses. See Part 8 of the ORM Cost Impact Analysis Guidance for additional guidance.

**Table 4: Impact on Small Businesses**

(1) Direct & Indirect Costs & Benefits (Monetized)	This Periodic Review decision does not change the impact on small businesses.  Direct Costs: \$0  Indirect Costs: If a business is associated with an outbreak or is a source of exposure for a reportable disease, this may continue to result in indirect costs. VDH is not able to quantify the indirect monetary cost as it could vary by the size and scope of each reportable disease outbreak.  Direct Benefits: \$0  Indirect Benefits: \$0	
(2) Present Monetized Values	Direct & Indirect Costs	Direct & Indirect Benefits
	(a) \$0 (but see explanation above)	(b) \$0 (but see explanation above)

(3) Other Costs & Benefits (Non-Monetized)	<p>Benefits:</p> <ul style="list-style-type: none"> <li>(1) Reduced morbidity and mortality associated with reportable disease in Virginia due to the public health system’s ability to surveil for potential outbreaks, clusters, or epidemics, and respond by implementing appropriate infection prevention and control protocols.</li> <li>(2) Businesses associated with an outbreak or sources of exposure for reportable disease will get education on ways to improve operations to protect public health.</li> </ul>
(4) Alternatives	<p>There are no alternatives to the regulations or the periodic review of the regulatory chapter.</p>
(5) Information Sources	<p>None</p>